Patents by Inventor Martin Ian Cooper

Martin Ian Cooper has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL SOLID FORMS OF BENDAMUSTINE HYDROCHLORIDE
    Publication number: 20200323824
    Abstract: Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.
    Type: Application
    Filed: November 18, 2019
    Publication date: October 15, 2020
    Inventors: Martin Ian Cooper, Laurent D. Courvoisier, Mark Eddleston, Robert E. McKean
  • Solid forms of bendamustine hydrochloride
    Patent number: 10517852
    Abstract: Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: December 31, 2019
    Assignee: Cephalon, Inc.
    Inventors: Martin Ian Cooper, Laurent D. Courvoisier, Mark Eddleston, Robert E. McKean
  • Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate
    Patent number: 10301287
    Abstract: The invention relates to solid forms of cenicriviroc mesylate, methods of their preparation, pharmaceutical compositions thereof and methods of their use.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: May 28, 2019
    Assignee: Tobira Therapeutics, Inc.
    Inventors: Pasit Phiasivongsa, Martin Ian Cooper, Emma Kay Sharp
  • NOVEL SOLID FORMS OF BENDAMUSTINE HYDROCHLORIDE
    Publication number: 20190015390
    Abstract: Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.
    Type: Application
    Filed: July 17, 2018
    Publication date: January 17, 2019
    Inventors: Martin Ian Cooper, Laurent D. Courvoisier, Mark Eddleston, Robert E. McKean
  • Solid forms of bendamustine hydrochloride
    Patent number: 10039750
    Abstract: Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: August 7, 2018
    Assignee: Cephalon, Inc.
    Inventors: Martin Ian Cooper, Laurent D. Courvoisier, Mark Eddleston, Robert E. McKean
  • Hydrochloride salt of((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo[2,3-D]pyrimidin-7-YL}-2-hydroxycyclopentyl) methyl sulfamate
    Patent number: 10016427
    Abstract: Disclosed is a compound of formula (I): crystalline forms thereof, and solvates thereof; pharmaceutical compositions comprising a pharmaceutically effective amount of the compound of formula (I), or a crystalline form thereof, or a solvate thereof, and a pharmaceutically acceptable carrier or diluent; and the use of a compound of formula (I), or a crystalline form thereof, or a solvate thereof, for treating a patient suffering from, or subject to, a pathological condition capable of being ameliorated by inhibiting an E1 activating enzyme, particularly NAE, including, e.g., cancer.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: July 10, 2018
    Assignee: Millennium Pharmacetuicals, Inc.
    Inventors: Ian G. Armitage, Reenu Chopra, Martin Ian Cooper, Marianne Langston, Steven P. Langston, Stepan Vyskocil
  • SOLID FORMS OF CENICRIVIROC MESYLATE AND PROCESSES OF MAKING SOLID FORMS OF CENICRIVIROC MESYLATE
    Publication number: 20180057481
    Abstract: The invention relates to solid forms of cenicriviroc mesylate, methods of their preparation, pharmaceutical compositions thereof and methods of their use.
    Type: Application
    Filed: August 30, 2017
    Publication date: March 1, 2018
    Inventors: Pasit PHIASIVONGSA, Martin Ian COOPER, Emma Kay SHARP
  • NOVEL SOLID FORMS OF BENDAMUSTINE HYDROCHLORIDE
    Publication number: 20170071913
    Abstract: Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.
    Type: Application
    Filed: November 23, 2016
    Publication date: March 16, 2017
    Inventors: Martin Ian Cooper, Laurent D. Courvoisier (Deceased), Mark Eddleston, Robert E. McKean
  • HYDROCHLORIDE SALT OF((1S,2S,4R)-4--2-HYDROXYCYCLOPENTYL) METHYL SULFAMATE
    Publication number: 20170000792
    Abstract: Disclosed is a compound of formula (I): crystalline forms thereof, and solvates thereof; pharmaceutical compositions comprising a pharmaceutically effective amount of the compound of formula (I), or a crystalline form thereof, or a solvate thereof, and a pharmaceutically acceptable carrier or diluent; and the use of a compound of formula (I), or a crystalline form thereof, or a solvate thereof, for treating a patient suffering from, or subject to, a pathological condition capable of being ameliorated by inhibiting an E1 activating enzyme, particularly NAE, including, e.g., cancer.
    Type: Application
    Filed: October 9, 2015
    Publication date: January 5, 2017
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Ian G. Armitage, Reenu Chopra, Martin Ian Cooper, Marianne Langston, Steven P. Langston, Stepan Vyskocil
  • Solid forms of bendamustine hydrochloride
    Patent number: 9533955
    Abstract: Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: January 3, 2017
    Assignee: Cephalon, Inc.
    Inventors: Martin Ian Cooper, Laurent D. Courvoisier, Mark Eddleston, Robert E. McKean
  • Novel Solid Forms Of Bendamustine Hydrochloride
    Publication number: 20160159748
    Abstract: Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.
    Type: Application
    Filed: February 17, 2016
    Publication date: June 9, 2016
    Inventors: Martin Ian Cooper, Laurent D. Courvoisier, Mark Eddleston, Robert E. McKean
  • HYDROCHLORIDE SALT OF((1S,2S,4R)-4--2-HYDROXYCYCLOPENTYL) METHYL SULFAMATE
    Publication number: 20160030432
    Abstract: Disclosed is a compound of formula (I): crystalline forms thereof, and solvates thereof; pharmaceutical compositions comprising a pharmaceutically effective amount of the compound of formula (I), or a crystalline form thereof, or a solvate thereof, and a pharmaceutically acceptable carrier or diluent; and the use of a compound of formula (I), or a crystalline form thereof, or a solvate thereof, for treating a patient suffering from, or subject to, a pathological condition capable of being ameliorated by inhibiting an E1 activating enzyme, particularly NAE, including, e.g., cancer.
    Type: Application
    Filed: October 9, 2015
    Publication date: February 4, 2016
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Ian G. Armitage, Reenu Chopra, Martin Ian Cooper, Marianne Langston, Steven P. Langston, Stepan Vyskocil
  • Hydrochloride salt of((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
    Patent number: 9187482
    Abstract: Disclosed is a compound of formula (I): crystalline forms thereof, and solvates thereof; pharmaceutical compositions comprising a pharmaceutically effective amount of the compound of formula (I), or a crystalline form thereof, or a solvate thereof, and a pharmaceutically acceptable carrier or diluent; and the use of a compound of formula (I), or a crystalline form thereof, or a solvate thereof, for treating a patient suffering from, or subject to, a pathological condition capable of being ameliorated by inhibiting an E1 activating enzyme, particularly NAE, including, e.g., cancer.
    Type: Grant
    Filed: May 13, 2010
    Date of Patent: November 17, 2015
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Ian G. Armitage, Reenu Chopra, Martin Ian Cooper, Marianne Langston, Steven P. Langston, Stepan Vyskocil
  • LACTATE SALT OF 4-[6-METHOXY-7-(3-PIPERIDIN-1-YL-PROPOXY)QUINAZOLIN-4-YL]PIPERAZINE-1-CARBOXYLIC ACID(4-ISOPROPOXYPHENYL)-AMIDE AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CANCER AND OTHER DISEASES OR DISORDERS
    Publication number: 20150133460
    Abstract: This invention provides a compound of formula (I): or a crystalline form thereof, or a pharmaceutical composition thereof, or an oral pharmaceutical dosage form thereof; processes for the synthesis or manufacture of the compound of formula (I), or a crystalline form thereof, or a pharmaceutical composition thereof, or an oral pharmaceutical dosage form thereof; and the use of said compound, or a crystalline form thereof, or a pharmaceutical composition thereof, or an oral pharmaceutical dosage form thereof, for the treatment of patients suffering from or subject to diseases, disorders or conditions involving cell survival, proliferation, and migration, including cardiovascular disease (e.g., arteriosclerosis and vascular reobstruction), cancer, (e.g., AML and malignant glioma) glomerulosclerosis, fibrotic disease and inflammation.
    Type: Application
    Filed: November 11, 2013
    Publication date: May 14, 2015
    Applicant: Millennium Phamaceuticals, Inc.
    Inventors: Ian Armitage, Abu J. Ferdous, Michael E. Bourland, Craig S.J. Boyle, Martin Ian Cooper, Marianne Langston
  • Novel Solid Forms Of Bendamustine Hydrochloride
    Publication number: 20150051258
    Abstract: Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.
    Type: Application
    Filed: November 3, 2014
    Publication date: February 19, 2015
    Inventors: Martin Ian Cooper, Laurent D. Courvoisier, Mark Eddleston, Robert E. McKean
  • Solid forms of bendamustine hydrochloride
    Patent number: 8883836
    Abstract: Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: November 11, 2014
    Assignee: Cephalon, Inc.
    Inventors: Martin Ian Cooper, Laurent D. Courvoisier, Mark Eddleston, Robert E. McKean
  • Novel Solid Forms Of Bendamustine Hydrochloride
    Publication number: 20140187598
    Abstract: Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.
    Type: Application
    Filed: March 7, 2014
    Publication date: July 3, 2014
    Applicant: Cephalon, Inc.
    Inventors: Martin Ian Cooper, Laurent D. Courvoisier, Mark Eddleston, Robert E. McKean
  • Solid forms of bendamustine hydrochloride
    Patent number: 8669279
    Abstract: Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.
    Type: Grant
    Filed: May 1, 2013
    Date of Patent: March 11, 2014
    Assignee: Cephalon, Inc.
    Inventors: Martin Ian Cooper, Laurent D. Courvoisier, Mark Eddleston, Robert E. McKean
  • Novel Solid Forms Of Bendamustine Hydrochloride
    Publication number: 20130245086
    Abstract: Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.
    Type: Application
    Filed: May 1, 2013
    Publication date: September 19, 2013
    Applicant: Cephalon, Inc.
    Inventors: Martin Ian Cooper, Laurent D. Courvoisier, Mark Eddleston, Robert E. McKean
  • Soluble Salts of Thieno [2,3-d] Pyrimidine Derivatives
    Publication number: 20120202825
    Abstract: The present invention is directed to novel salts of thieno[2,3-d]pyrimidine derivatives, including 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine salts. The present invention is also directed to compositions including such polymorphs and methods for using such salts, e.g., in the treatment of gastrointestinal and/or genitourinary disorders.
    Type: Application
    Filed: February 4, 2011
    Publication date: August 9, 2012
    Inventors: Martin Ian Cooper, Christopher Stephen Frampton